4-(1-methylethyl)-2-methyl-1H-pyrrole | 98425-66-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-(1-methylethyl)-2-methyl-1H-pyrrole
• 英文别名: 4-isopropyl-2-methyl-pyrrole；4-Isopropyl-2-methyl-pyrrol；3-isopropyl-5-methylpyrrole；2-Methyl-4-isopropylpyrrole；2-methyl-4-propan-2-yl-1H-pyrrole
• CAS: 98425-66-2
• 化学式: C₈H₁₃N
• mdl: MFCD18800815
• 分子量: 123.198
• InChiKey: RZKCKJLFVKLXIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  4-(1-methylethyl)-2-methyl-1H-pyrrole 在 sodium hydride 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 1-amino-N,5-dimethyl-3-propan-2-ylpyrrole-2-carboxamide
  参考文献：
  名称：

  Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF1) receptor antagonists

  摘要：

  To identify structurally novel corticotropin-releasing factor 1 (CRF1) receptor antagonists, a series of bicyclic core analogs pyrrolo[1,2-b]pyridazines and pyrrolo[2,1-f]triazin-4(3H)-ones, which were designed based on a monocyclic core antagonist, was synthesized and evaluated. Among the compounds tested, 2-difluoromethoxy-4-methylpyridin-5-yl analog 27 was found to show efficacy in a dose-dependent manner in an elevated plus maze test in rats. The discovery process and structure-activity relationship is presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.015
• 作为产物：
  描述：

  (6CI)-4-异丙基-2-甲基吡咯-3-羧酸 在 quartz sand 作用下， 生成 4-(1-methylethyl)-2-methyl-1H-pyrrole
  参考文献：
  名称：

  Sugawa et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1955, vol. 75, p. 845,849

  摘要：

  DOI：

文献信息

• BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE
  申请人：National Health Research Institutes

  公开号：US20200071312A1

  公开（公告）日：2020-03-05

  Benzimidazole compounds of formula (I), shown below, are disclosed. The compounds are potent human glutaminyl cyclase inhibitors. Also disclosed is a pharmaceutical composition containing one of these compounds and a pharmaceutical acceptable carrier, as well as a method of treating Alzheimer's disease or Huntington's disease by administering to a subject in need thereof an effective amount of such a compound.

  以下显示的化学式（I）的苯并咪唑化合物已被披露。这些化合物是强效的人类谷氨酰环化酶抑制剂。还披露了一种含有其中一种这些化合物和一种药用可接受载体的药物组合物，以及通过向需要的受试者施用这种化合物的有效量来治疗阿尔茨海默病或亨廷顿病的方法。
• 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF
  申请人：GiraFpharma LLC

  公开号：US20190023702A1

  公开（公告）日：2019-01-24

  1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

  提供了作为腺苷受体调节剂的1,8-萘啶酮化合物。这些化合物可能作为治疗经由G蛋白偶联受体信号通路介导的疾病的治疗剂，并且可能在肿瘤学中发挥特定作用。
• 2-pyrazolin-5-ones
  申请人：Abbott GmbH & Co. KG

  公开号：US07060822B1

  公开（公告）日：2006-06-13

  Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.

  具有结构式I的化合物及其生理上可接受的盐是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物抑制的几种酪氨酸激酶参与血管生成过程。因此，这些化合物可以改善血管生成或内皮细胞过度增殖是因素的疾病状态。这些化合物可用于治疗癌症和过度增殖性疾病。
• METHODS FOR THE CONVERSION OF A SUBSTITUTED FURAN TO A SUBSTITUTED PYRROLE
  申请人：Kreischer Bruce E.

  公开号：US20120083609A1

  公开（公告）日：2012-04-05

  The present invention discloses processes for producing substituted pyrrole compounds, such as 2,5-disubstituted pyrroles. Synthetic processes which directly convert substituted furan compounds to substituted pyrrole compounds, via a reaction of the substituted furan compound with ammonia and/or an ammonium salt in the presence of a catalyst, also are described.

  本发明揭示了生产取代吡咯化合物的过程，例如2,5-二取代吡咯化合物。还描述了一种合成过程，该过程通过将取代呋喃化合物与氨和/或铵盐在催化剂存在下反应，直接转化为取代吡咯化合物。
• Preparation of an Olefin Oligomerization Catalyst
  申请人：Sydora Orson L.

  公开号：US20130150642A1

  公开（公告）日：2013-06-13

  This disclosure provides for new catalyst systems and new methods for preparing and using the catalyst systems for generating a trimerization product. In an aspect, the new catalyst systems comprise a chromium carboxylate that is prepared by anhydrous metathesis. In another aspect, the catalyst system comprise a chromium carboxylate that is prepared by anhydrous metathesis and a metal pyrrolide compound. The catalyst systems imparts improved performance and/or reduced catalyst system cost to an olefin trimerization process.

  本公开提供了新的催化剂系统和新的方法，用于制备和使用催化剂系统生成三聚物产物。在一个方面，新的催化剂系统包括通过无水交换反应制备的铬羧酸盐。在另一个方面，催化剂系统包括通过无水交换反应制备的铬羧酸盐和金属吡咯烷化合物。这些催化剂系统赋予烯烃三聚化过程改进的性能和/或降低了催化剂系统成本。